Tag: discontinuation

Ayurdhi Dhar interviews psychiatrist Swapnil Gupta on psychiatric drug discontinuation, drug cocktail risks, patient choice, and the need for trust and transparency.

New research finds the negative drug effects most commonly associated with initiating antidepressant discontinuation are anxiety, suicidal thoughts, vomiting, and rashes.

New study reveals: 2 in 3 people need more than the current antidepressant benefits to consider them worthwhile.

Growing rates of long-term psychiatric drug prescriptions and documented issues with withdrawal demonstrate a need for safe deprescribing practices.

In online communities, patients learn their strange symptoms may be due to the medications they are taking, and are offered solutions that provide hope.

The problems related to the use of antidepressants cannot be solved by an oversimplified psychiatry brainwashed by the pharmaceutical industry.

Supportive patient-practitioner relationships are crucial to the successful discontinuation of psychiatric medication.

Researchers argue that common study methods for psychiatric drugs may inadvertently minimize withdrawal effects and inflate drug efficacy.

A meta-analysis published last month showed that psychotherapy has an enduring effect on depression—in contrast to depression pills.

Leading researchers point out that a new antidepressant study in NEJM failed to account for withdrawal symptoms, casting doubt on the results.

New guidance on how to taper and discontinue from psychiatric drugs from leading researchers Mark Horowitz and David Taylor.

Research suggests that slowly tapering off an antipsychotic reduces the risk of withdrawal psychosis compared to abrupt discontinuation.

A new study investigates how antidepressant withdrawal effects often get confounded with depression relapse in clinical trials.

A new article in Lancet Psychiatry debunks past studies claiming that those on low doses of antipsychotics are more likely to relapse.

Peter Gøtzsche gives advice on what withdrawal symptoms may look like and explains the dangers of—and alternatives to—forced treatment.

Psychiatrists have made hundreds of millions of people dependent on psychiatric drugs and yet have done virtually nothing to find out how to help the patients come off them again.

Peter Gøtzsche: The MIND organization in Denmark and the psychiatric guild suppressed information regarding the discontinuation of psychiatric drugs.

Very few doctors know anything about withdrawal and make horrible mistakes. If they taper at all, they do it far too quickly because the few guidelines that exist recommend far too quick tapering.

Anti-stigma campaigns reinforce a belief that people with mental health issues must have treatment and thus, push discussion of withdrawal and negative aspects of psychiatric drugs into anonymous spaces.

Researchers find a lack of current literature on safe, effective ways to manage antidepressant withdrawal and make suggestions for future research.

A new article discusses the lack of research dedicated to discontinuing psychiatric drugs and reviews existing strategies.

Online withdrawal forums document an assortment of risks associated with discontinuation of psychiatric drugs. Such information is readily available and must be disclosed during informed consent.

Online communities are stepping in to help people facing withdrawal effects amass information and receive support for their withdrawal experiences.

Sami Timimi provides a discussion of the ways medication may be helpful for some, and advice and information on discontinuing psychiatric drugs.

A new study looks at how online communities provide information and support for patients experiencing psychiatric drug withdrawal.